Evidence map›Paper›PMID 29364875›Full record

ArticleNature2018

Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders.

Eliezer Calo, Bo Gu, Margot E Bowen, Fardin Aryan, Antoine Zalc, Jialiang Liang, Ryan A Flynn, Tomek Swigut, Howard Y Chang, Laura D Attardi and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 167 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. RUNX1-deficiency drives immune-active ERbioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. HemaSphere · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Mechanisms of ribosomopathy and phase separation-related ribosomopathy.Journal of Zhejiang University. Science. B · 2025
    Review
  17. Review
  18. Article
  19. TheFrontiers in medicine · 2025
    Review
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Eliezer CaloDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Bo GuDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Margot E BowenDepartment of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Fardin AryanDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Antoine ZalcDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Jialiang LiangDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Ryan A FlynnDepartment of Chemistry, Stanford University, Stanford, California 94305, USA.
Tomek SwigutDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University, 269 Campus Drive, Stanford, California 94305, USA.
Laura D AttardiDepartment of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Joanna WysockaDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Stanford University · USMassachusetts Institute of Technology · USKoch Institute for Integrative Cancer Research At MIT

Funding

Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Special EquipmentP50HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2014 to 2018
$15.2M
Integrative approaches to elucidate p53 transcriptional networks during carcinogenesisR35CA197591 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI · 2015 to 2026
$11.6M
LncRNA regulation of environmental responseR01ES023168 · NIEHS · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2013 to 2016
$2.2M
Mechanisms of enhancer activation in early developmentR01GM112720 · NIGMS · STANFORD UNIVERSITY · PI WYSOCKA, JOANNA · 2015 to 2018
$1.2M
Howard Hughes Medical InstituteNCI NIH HHS R35 CA197591NCI NIH HHS T32 CA009302NHGRI NIH HHS P50 HG007735NIEHS NIH HHS R01 ES023168NIGMS NIH HHS R01 GM112720
6 · The paper itself

Abstract

Many craniofacial disorders are caused by heterozygous mutations in general regulators of housekeeping cellular functions such as transcription or ribosome biogenesis. Although it is understood that many of these malformations are a consequence of defects in cranial neural crest cells, a cell type that gives rise to most of the facial structures during embryogenesis, the mechanism underlying cell-type selectivity of these defects remains largely unknown. By exploring molecular functions of DDX21, a DEAD-box RNA helicase involved in control of both RNA polymerase (Pol) I- and II-dependent transcriptional arms of ribosome biogenesis, we uncovered a previously unappreciated mechanism linking nucleolar dysfunction, ribosomal DNA (rDNA) damage, and craniofacial malformations. Here we demonstrate that genetic perturbations associated with Treacher Collins syndrome, a craniofacial disorder caused by heterozygous mutations in components of the Pol I transcriptional machinery or its cofactor TCOF1 (ref. 1), lead to relocalization of DDX21 from the nucleolus to the nucleoplasm, its loss from the chromatin targets, as well as inhibition of rRNA processing and downregulation of ribosomal protein gene transcription. These effects are cell-type-selective, cell-autonomous, and involve activation of p53 tumour-suppressor protein. We further show that cranial neural crest cells are sensitized to p53-mediated apoptosis, but blocking DDX21 loss from the nucleolus and chromatin rescues both the susceptibility to apoptosis and the craniofacial phenotypes associated with Treacher Collins syndrome. This mechanism is not restricted to cranial neural crest cells, as blood formation is also hypersensitive to loss of DDX21 functions. Accordingly, ribosomal gene perturbations associated with Diamond-Blackfan anaemia disrupt DDX21 localization. At the molecular level, we demonstrate that impaired rRNA synthesis elicits a DNA damage response, and that rDNA damage results in tissue-selective and dosage-dependent effects on craniofacial development. Taken together, our findings illustrate how disruption in general regulators that compromise nucleolar homeostasis can result in tissue-selective malformations.

Indexed as

DNA DamageStress, PhysiologicalAnimalsApoptosisBenzothiazolesCell NucleolusCell NucleusChromatinDEAD-box RNA HelicasesDNA-Directed RNA PolymerasesDNA, RibosomalEmbryonic Stem CellsHeLa CellsHumansIntracellular Signaling Peptides and ProteinsMandibulofacial DysostosisBenzothiazolesChromatinCX 5461DDX21 protein, humanddx21 protein, zebrafishDEAD-box RNA HelicasesDNA-Directed RNA PolymerasesDNA, RibosomalIntracellular Signaling Peptides and ProteinsNaphthyridinesNuclear ProteinsPhosphoproteinsPOLR1D protein, humanRibosomal ProteinsRNA HelicasesRNA Polymerase IRNA, RibosomalTCOF1 protein, humanTcof1 protein, mouseTCOF1 protein, XenopusTumor Suppressor Protein p53Zebrafish Proteins

Identifiers

PMID29364875
PMCPMC5927778
OpenAlexW2786456002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.